Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

Fig. 2

a Immunohistochemistry for MLH1 protein on the primary tumour showing a heterogeneous expression profile. b Microsatellite testing results according to different areas of the primary tumour. c MLH1 proficiency documented in baseline diagnostic biopsy. d MLH1 loss documented in synchronous peritoneal metastasis. Scale bar indicates 100 μm

Back to article page